Six-Year Follow-Up of Impact of Co-proxamol Withdrawal in England and Wales on Prescribing and Deaths: Time-Series Study

English version České info

Background:
The analgesic co-proxamol (paracetamol/dextropropoxyphene combination) has been widely involved in fatal poisoning. Concerns about its safety/effectiveness profile and widespread use for suicidal poisoning prompted its withdrawal in the UK in 2005, with partial withdrawal between 2005 and 2007, and full withdrawal in 2008. Our objective in this study was to assess the association between co-proxamol withdrawal and prescribing and deaths in England and Wales in 2005–2010 compared with 1998–2004, including estimation of possible substitution effects by other analgesics.

Methods and Findings:
We obtained prescribing data from the NHS Health and Social Care Information Centre (England) and Prescribing Services Partneriaeth Cydwasanaethau GIG Cymru (Wales), and mortality data from the Office for National Statistics. We carried out an interrupted time-series analysis of prescribing and deaths (suicide, open verdicts, accidental poisonings) involving single analgesics. The reduction in prescribing of co-proxamol following its withdrawal in 2005 was accompanied by increases in prescribing of several other analgesics (co-codamol, paracetamol, codeine, co-dydramol, tramadol, oxycodone, and morphine) during 2005–2010 compared with 1998–2004. These changes were associated with major reductions in deaths due to poisoning with co-proxamol receiving verdicts of suicide and undetermined cause of −21 deaths (95% CI −34 to −8) per quarter, equating to approximately 500 fewer suicide deaths (−61%) over the 6 years 2005–2010, and −25 deaths (95% CI −38 to −12) per quarter, equating to 600 fewer deaths (−62%) when accidental poisoning deaths were included. There was little observed change in deaths involving other analgesics, apart from an increase in oxycodone poisonings, but numbers were small. Limitations were that the study was based on deaths involving single drugs alone and changes in deaths involving prescribed morphine could not be assessed.

Conclusions:
During the 6 years following the withdrawal of co-proxamol in the UK, there was a major reduction in poisoning deaths involving this drug, without apparent significant increase in deaths involving other analgesics.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Six-Year Follow-Up of Impact of Co-proxamol Withdrawal in England and Wales on Prescribing and Deaths: Time-Series Study. PLoS Med 9(5): e32767. doi:10.1371/journal.pmed.1001213
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001213

Souhrn

Zdroje

1. Medicines and Healthcare products Regulatory Agency 2005 Withdrawal of co-proxamol products and interim updated prescribing information CEM/CMO/2005/2. Available: http://www.mhra.gov.uk/home/groups/pl-a/documents/websiteresources/con019461.pdf. Accessed 2 March 2005

2. Committee on Safety of Medicines 2006 Withdrawal of co-proxamol (Distalgesic, Cosalgesic, Dolgesic). Current Problems in Pharmacovigilance 31 11 11

3. SimkinSHawtonKSuttonLGunnellDBennewithO 2005 Co-proxamol and suicide: a review to inform initiatives to prevent the continuing toll of overdose deaths. Q J Med 98 159 170

4. HawtonKSimkinSDeeksJJ 2003 Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self-poisonings. BMJ 326 1006 1008

5. Drug and Therapeutics Bulletin 1983 Distalgesic and its equivalents: time for action. Drug Ther Bull 21 17 19

6. BatemanDNAfshariR 2003 Licence needs to be changed. BMJ 327 287 287

7. HawtonKSimkinSGunnellDSuttonLBennewithO 2005 A multicentre study of coproxamol poisoning suicides based on coroners' records in England. Br J Clin Pharmacol 59 207 212

8. YoungRJLawsonAA 1980 Distalgesic poisoning - cause for concern. BMJ 280 1045 1047

9. Committee on Safety of Medicines 2004 Risk: benefit of Co-proxamol. Current Problems in Pharmacovigilance 30 8 8

10. EMEA European Medicines Agency 2009 European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines (press release) EMEA/401062/2009 London EMEA European Medicines Agency

11. U.S. Food and Drug Administration (FDA) 2009 FDA takes action on Darvon, other pain medications containing propoxyphene. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170769.htm. Accessed 3 February 2009

12. U.S. Food and Drug Administration (FDA) 2010 Xanodyne agrees to withdraw propoxyphene from the U.S. market. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234350.htm. Accessed 15 May 2011

13. Health Canada 2010 Darvon-N (dextropropoxyphene) - recall and withdrawal in Canada - for the public. Available: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2010/darvon-n_pc-cp-eng.php. Accessed 11 May 2011

14. The Information Centre for health and social care PSU 2006 Prescription cost analysis: England 2005 Leeds Department of Health

15. The Information Centre for health and social care PSU 2007 Prescription cost analysis: England 2006 Leeds Department of Health

16. HawtonKBergenHSimkinSBrockAGriffithsC 2009 Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: time series analysis. BMJ 338 b2270

17. SandilandsEABatemanDN 2008 Co-proxamol withdrawal has reduced suicide from drugs in Scotland. Br J Clin Pharmacol 66 290 293

18. CorcoranPReulbachUKeeleyHSPerryIJHawtonK 2010 Use of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market. BMC Clin Pharmacol 10 Art. 6

19. HawtonKBergenHWatersKMurphyECooperJ 2011 Impact of withdrawal of the analgesic co-proxamol in the UK on non-fatal self-poisoning. Crisis 32 81 87

20. HawtonK 2005 Restriction of access to methods of suicide as a means of suicide prevention. HawtonK Prevention and treatment of suicidal behaviour: from science to practice Oxford Oxford University Press 279 291

21. Office for National Statistics 2011 Deaths related to drug poisoning in England and Wales, 2010. 1 17 Statistical bulletin http://www.ons.gov.uk/ons/rel/subnational-health3/deaths-related-to-drug-poisoning/2010/pdf-download.pdf

22. HillCCookL 2011 Narrative verdicts and their impact on mortality statistics in England and Wales. Health Stat Q 49 81 100

23. AdelsteinAMardonC 1975 Suicides 1961–74. Popul Trends 2 13 18

24. BrockABakerAGriffithsCJacksonGFeganG 2006 Suicide trends and geographical variations in the United Kingdom, 1991–2004. Health Stat Q 31 6 22

25. Stata Corporation 2007 Stata Statistical software: release 10 College Station (Texas) Stata Corporation

26. RamsayCRMatoweLGrilliRGrimshawJMThomasRE 2003 Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. Int J Technol Assess 19 613 623

27. WagnerAKSoumeraiSBZhangFRoss-DegnanD 2002 Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27 299 309

28. GottliebS 2005 Warnings issued over COX 2 inhibitors in US and UK. BMJ 330 9 9

29. HawtonKSimkinSDeeksJCooperJJohnstonA 2004 UK legislation on analgesic packs: Before and after study of long term effect on poisonings. BMJ 329 1076 1079

30. GunnellDPlattSHawtonK 2009 The economic crisis and suicide. Consequences may be serious and warrant early attention. BMJ 338 1456 1457

31. StucklerDBasuSSuhrckeMCouttsAMcKeeM 2011 Effects of the 2008 recession on health: a first look at European data. Lancet 378 124 125

32. KreitmanN 1976 The coal gas story: United Kingdom suicide rates 1960–1971. Br J Prev Soc Med 30 86 93

33. GunnellDFernandoRHewagamaMPriyangikaWDDKonradsenF 2007 The impact of pesticide regulations on suicide in Sri Lanka. Int J Epidemiol 36 1235 1242

34. Statutory instrument 1997 No. 2045 1997 The medicines (sales or supply) (miscellaneous provisions) amendment (no 2) regulations 1997 London The Stationery Office

35. HawtonKTownsendEDeeksJJApplebyLGunnellD 2001 Effects of legislation restricting pack sizes of paracetamol and salicylates on self poisoning in the United Kingdom: before and after study. BMJ 322 1203 1207

36. US Department of Justice Drug Enforcement Administration 2009 Drugs and chemicals of concern. Oxycodone. Available: http://www.deadiversion.usdoj.gov/drugs_concern/oxycodone/summary.htm. Accessed 20 December 2011

37. DaigleMS 2005 Suicide prevention through means restriction: assessing the risk of substitution: a critical review and synthesis. Accid Anal Prev 37 625 632

38. ZhangFWagnerASoumeraiSBRoss-DegnanD 2002 Estimating confidence intervals around relative changes in outcomes in segmented regression analyses of time series data. Available: http://www.nesug.info/Proceedings/nesug02/st/st005.pdf. Accessed 4 July 2011